Cytochrome P-450 CYP2C9
-
Subject Areas on Research
- A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.
- A pharmacogenetic versus a clinical algorithm for warfarin dosing.
- CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose.
- Clinical application of cardiovascular pharmacogenetics.
- Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention.
- Cytochrome P450 2C9 plays an important role in the regulation of exercise-induced skeletal muscle blood flow and oxygen uptake in humans.
- Determinants of the over-anticoagulation response during warfarin initiation therapy in Asian patients based on population pharmacokinetic-pharmacodynamic analyses.
- Eight common genetic variants associated with serum DHEAS levels suggest a key role in ageing mechanisms.
- Estimation of the warfarin dose with clinical and pharmacogenetic data.
- Genetic-based dosing in orthopedic patients beginning warfarin therapy.
- Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: evidence for specificity toward P-450 2E1.
- Large-scale pharmacogenomic study of sulfonylureas and the QT, JT and QRS intervals: CHARGE Pharmacogenomics Working Group.
- Pharmacogenomics for personalized pain medicine.
- Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype.
- Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes.
- Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs).
- The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.
- The long and winding road to warfarin pharmacogenetic testing.
- The worry about clopidogrel "nonresponsiveness": identification and treatment in the post-percutaneous coronary intervention patient.
- Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.
- Use of pharmacogenetics to guide warfarin therapy.
- Variants in ADRB1 and CYP2C9: Association with Response to Atenolol and Losartan in Marfan Syndrome.